214472-37-4

Basic information

• Product Name: Methyl 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzoate
• Synonyms: Methyl 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzoate;Methyl 4-Methoxy-3-(3-Morpholinopropoxy)-2-nitrobenzoate;4-Methoxy-5-(3-(morpholin-4-yl)propoxy)-2-nitrobenzoic acid methyl ester
• CAS NO: 214472-37-4
• Molecular Formula: C₁₆H₂₂N₂O₇
• Molecular Weight: 354.35508
• EINECS: -0
• Product Categories: Gefitinib INTERMEDIATES
• Mol File: 214472-37-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzoate(214472-37-4)
• EPA Substance Registry System: Methyl 4-Methoxy-5-(3-Morpholinopropoxy)-2-nitrobenzoate(214472-37-4)

Safety Data

• Hazardous Substances Data: 214472-37-4(Hazardous Substances Data)

Usage

General Description

"Methyl 4-methoxy-5-(3-morpholinopropoxy)-2-nitrobenzoate" is a complex chemical compound with a structure that includes multiple functional groups such as a nitro group, morpholino group, methoxy group, and an ester group. methyl 4-methoxy-5-(3-morpholinopropoxy)-2-nitrobenzoate inherits various chemical characteristics from these functional groups. However, there are no specific well-known properties or applications documented for this particular compound. Like other organic compounds, its properties can be influenced by factors such as its exact molecular structure, purity, and the conditions under which it is stored and used. These factors can impact its reactivity, solubility, and other physical and chemical properties. It is essential to handle this chemical carefully, with proper safety precautions, due to its potential reactivity and toxicity which are general attributes of nitro compounds.

InChI:InChI=1S/C16H22N2O7/c1-22-14-11-13(18(20)21)12(16(19)23-2)10-15(14)25-7-3-4-17-5-8-24-9-6-17/h10-11H,3-9H2,1-2H3

Upstream product

• 214472-17-0 4-methoxy-5-[3-(4-morpholinyl)propoxy]benzoic acid methyl ester 
• 110-91-8 morpholine 
• 380844-24-6 methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate 
• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 380844-22-4 methyl 3-(3-chloropropoxy)-4-methoxybenzoate 
• 645-08-9 Isovanillic acid 
• 215659-03-3 methyl 5-hydroxy-4-methoxy-2-nitrobenzoate 
• 57616-74-7 N-(3-chloropropyl)morpholine hydrochloride 

Downstream Products

• 214472-41-0 methyl 5-(3-morpholinopropoxy)-2-amino-4-methoxy-benzoate 
• 199327-61-2 7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one 
• 184475-35-2 gefitinib 
• 199327-59-8 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline 
• 252264-46-3 ethyl 2-(dimethylaminomethyleneamino)-4-methoxy-5-(3-morpholin-4-yl-propoxy)benzoate 
• 214486-62-1 4-(4-chloro-2-fluoro-5-hydroxy-phenylamino)-7-methoxy-6-(3-morpholin-4-yl)-propoxyl-quinoline-3-carbonitrile 

Relevant articles and documents

A new heterocyclic compound initiates ROS accumulation and cause apoptotic cell death in human bone cancer cells

A new heterocyclic compound 7-methoxy-6-(3-morpholinopropoxy)quinazolin-4(3H)-one (1), designed using methyl 5-hydroxy-4-methoxy-2-nitrobenzoate (2) as the starting material, was successfully obtained via multiple synthesis route and finally characterized by fourier transform infrared (FT-IR) spectroscopy, 1H nuclear magnetic resonance (NMR), and single crystal X-ray crystallography. We investigated its effect on cell viability and proliferation with Cell Counting Kit-8 (CCK8) assay. The results revealed that compound 1 could block the proliferation of Saos-2 bone cancer cells. In addition, Annexin V-FITC/PI assay and Western blot analysis were performed to detect whether compound 1 could induce cell apoptosis. The results indicated that compound 1 could increase the number of apoptotic cells remarkably. Moreover, we examined the impact of compound 1 on ROS generation. Results revealed that compound 1 up-regulated the reactive oxygen species (ROS) genes expression and promoted the accumulation of ROS in Saos-2 cells. Finally, molecular docking has been utilized to study the binding mode of compound 1 with tubulin.

A PROCESS FOR THE PREPARATION OF GEFITINIB

The present invention provides an improved, industrial advantageous process for the preparation of gefitinib of formula (I), and its pharmaceutically acceptable salts thereof in high yield and purity.

Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: Synthesis of18F-Iressa and related molecular probes

Inhibitors of tyrosine kinase enzymatic activity represent a promising new class of antineoplastic agents. Although clinical studies performed over the last decade give more insight on the potential therapeutic applications of such drugs, identification of the individual patients who might benefit from them remains a major challenge. We have developed a synthetic strategy for the production of a wide variety of radiolabeled 6,7-disubstituted 4-anilinoquinazolines suitable for noninvasive imaging of tyrosine kinase receptors to predict therapy effectiveness. Three new F-18 labeled radiopharmaceuticals based on the therapeutic agents Tarceva, Iressa, and ZD6474 were synthesized. Decay-corrected yields varied between 25 and 40% for a total synthesis time of 120 min, thus providing F-18 labeled tyrosine kinase inhibitors in quantities and times practical for use as PET radiopharmaceuticals. Copyright